Tvardi Therapeutics

About:

Tvardi Therapeutics is a Private, Clinical Stage Biotechnology Company.

Website: https://www.tvarditherapeutics.com

Top Investors: Sporos Bioventures, ArrowMark Partners, 683 CAPITAL, THE CATALYTIC IMPACT FOUNDATION (CIF), Piedmont Capital Investments

Description:

Tvardi Therapeutics they are focused on the development of orally delivered, small molecule inhibitors of STAT3. They provide medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases.

Total Funding Amount:

$81.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Houston, Texas, United States

Founded Date:

2017-01-01

Founders:

David Tweardy, Ronald A. DePinho

Number of Employees:

11-50

Last Funding Date:

2021-06-15

IPO Status:

Private

Industries: